Last update Sept. 14, 2022
Very High Risk
We do not have alternatives for Diethylstilbestrol.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Diethylstilbestrol is also known as
Diethylstilbestrol in other languages or writings:
Diethylstilbestrol belongs to these groups or families:
Main tradenames from several countries containing Diethylstilbestrol in its composition:
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Diethylstilbestrol (DES) is a synthetic nonsteroidal estrogen that has been used to palliate breast and prostate cancer. It has been used in the past to prevent miscarriage or premature labor, to suppress postpartum lactation, and to prevent or treat breast engorgement.
Since the last update we have not found published data on its excretion in breastmilk.
It is a carcinogenic, withdrawn from the market in many countries. DES exposure during pregnancy has been associated with an increased risk of breast cancer in mothers and with an increased lifetime risk of cervicovaginal cancer in daughters exposed in utero. (Tournaire 2014, Troisi 2007, Giusti 1995, Clark 1979)